SARS‐CoV‐2 poses new challenges in all aspects of healthcare. Patients with preexisting cardio‐vascular conditions are at higher risk of developing severe symptoms and worse outcome. Data also suggest that cancer patients are particularly vulnerable, but differences between tumor entities and cancer treatments may exist. Little is known how cancer treatment engaging immune checkpoints affects the course of COVID‐19.